Navigation Links
4 Pulmonary Hypertension Programs Receive PHA’s PHCC Accreditation
Date:3/19/2020

The Pulmonary Hypertension Association (PHA) announces that Tufts Medical Center in Boston; Cleveland Clinic in Cleveland; University of Nebraska Medical Center in Omaha, Nebraska; and National Jewish Health in Denver have received accreditation as PHA Centers of Comprehensive Care (CCC) as part of its Pulmonary Hypertension Care Centers (PHCC) program. They received accreditation from PHA after demonstrating their ability to deliver quality care to patients living with pulmonary hypertension (PH), a complex, often misdiagnosed, life-threatening disease.

Since PHA’s accreditation program launched in 2014, 80 programs in 32 states have received PHCC accreditation. The program includes 59 adult and eight pediatric CCCs along with 13 adult Regional Clinical Programs (RCP).

The complex disease is thought to affect about 25 million adults and children worldwide and can occur among those with left-heart disease, along with sleep apnea, chronic obstructive pulmonary disease (COPD), scleroderma and other associated diseases. PH is significantly underdiagnosed and misunderstood. Symptoms, including shortness of breath, fatigue and chest pain, are not necessarily specific to PH and can lead to dangerous delays in a correct diagnosis.

Although no cure exists, early diagnosis and proper treatment can extend and improve a patient's quality of life. In addition, advances in treatment and a better understanding of PH have led to effective therapies and improved survival for many types of PH, once diagnosed.

“We are thrilled to see the PHCC network continue to grow. This program is an important step toward providing quality care for PH patients and offering scientists and clinicians opportunities to advance clinical research,” says Elizabeth Joseloff, Ph.D., vice president, Quality Care & Research, for PHA.

PHA-accredited sites are eligible for participation in the PHA registry (PHAR). PHAR collects data from individuals with pulmonary arterial hypertension (PAH), pediatric PH due to developmental lung disease and chronic thromboembolic pulmonary hypertension (CTEPH) who are starting evaluation and/or treatment at PHCCs across the United States. Over time, PHAR will help researchers evaluate trends and practice patterns to determine the treatments that work best and support PH research.

About the Pulmonary Hypertension Association

Headquartered in?Silver Spring, Maryland, the Pulmonary Hypertension Association (PHA) is the oldest and largest nonprofit patient association dedicated to the pulmonary hypertension (PH) community. Pulmonary hypertension is a rare, chronic and life-threatening disease of the lungs for which no cure currently exists. PHA's mission is to extend and improve the lives of those affected by PH. To achieve this mission, PHA engages people with PH and their families, caregivers, health care providers, and researchers worldwide who work together to advocate for the PH community, provide support to patients, caregivers and families, offer up-to-date education and information on PH, improve quality patient care, and fund and promote research. For more information, visit the PHA website.

Read the full story at https://www.prweb.com/releases/4_pulmonary_hypertension_programs_receive_phas_phcc_accreditation/prweb16993831.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine technology :

1. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
2. For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs
3. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
4. FDA Advisory Committee Unanimously Recommends Approval Of Bayers Riociguat In Two Pulmonary Hypertension Indications
5. Final Patient Completes Prosonix Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
6. Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension
7. Olodaterol Shows Sustained Improvements in Lung Function in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
8. Idiopathic pulmonary fibrosis (IPF) community emphasizes the power of united support for patients during IPF World Week 2013
9. Bayers Investigational Drug Riociguat Granted FDA Orphan Drug Designation for Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
10. The Modern Algorithm For Management Of Massive And Submassive Pulmonary Embolism
11. Genoa Pharmaceuticals Receives Orphan-Drug Designation for Pirfenidone in the Inhaled Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... ... April 01, 2020 , ... As ... provider of urgent care and accessible primary care, launches its telemedicine platform, AFC/TeleCare, ... healthcare clinics will now provide virtual visits, allowing our medical providers to easily ...
(Date:3/30/2020)... ... March 30, 2020 , ... Energage, the leader in ... launched a series of survey question packs that enable organizations to keep the ... decisions. As the current situation continues to evolve, The Energage Operational Readiness Survey ...
(Date:3/30/2020)... , ... March 30, 2020 , ... ... that it is now offering 'Ask A Technician' service. , "We are very ... LLC and added, "A certified technician at the Institute of Tattoo Removal is ...
Breaking Medicine Technology:
(Date:4/2/2020)... ... April 02, 2020 , ... Representatives fighting for ... their parents, grandparents, and guardians, to file a proof of claim in order ... will be made available by Purdue as part of its bankruptcy settlement. , ...
(Date:4/1/2020)... ... April 01, 2020 , ... American ... safe while treating Coronavirus-infected patients. , Staffers are in particular need of face ... Earlier this week, The Wall Street Journal reported that New York City mayor ...
(Date:3/30/2020)... ... March 30, 2020 , ... Achieve Medical Center now offers ... provide comprehensive and compassionate mental health and wellness services in the midst of ... for telemedicine services including initial consultations, evaluations, and follow-up care. It also allows ...
(Date:3/28/2020)... ... March 27, 2020 , ... The construction industry ... spread of the coronavirus. Operating under the designation as an essential business as ... and environmental protection projects in the downstate New York region. , While certain ...
(Date:3/28/2020)... ... 28, 2020 , ... Confluent Health is proud to announce ... company since 1985 specializing in the treatment of orthopedic, sports, and work-related injuries ... 30 years ago, we have been committed to providing excellent quality of patient ...
Breaking Medicine News(10 mins):